🇺🇸 FDA
Patent

US 9205091

Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer

granted A61KA61K31/4965A61K31/551

Quick answer

US patent 9205091 (Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K31/4965, A61K31/551, A61P, A61P35/00